POMC and Bardet-Biedl syndrome: For example, setmelanotide, a MC4R agonist is FDA approved for treatment of monogenic obesity related to POMC deficiency, leptin receptor (LEPR) deficiency (108, 109), and Bardet Biedl syndrome (110).